Epigenetic biomarkers in prostate cancer: Current and future uses.

Karen Chiam; Carmella Ricciardelli; Tina Bianco-Miotto

doi:10.1016/j.canlet.2012.02.011

Epigenetic biomarkers in prostate cancer: Current and future uses.

Karen Chiam, Carmella Ricciardelli, Tina Bianco-Miotto

Research output: Contribution to journal › Review article › peer-review

62 Citations (Scopus)

Abstract

Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.

Original language	English
Pages (from-to)	248-256
Number of pages	9
Journal	Cancer Letters
Volume	342
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.02.011
Publication status	Published - 28 Jan 2014

Keywords

Biomarkers
DNA methylation
Epigenetics
Histone modifications
MicroRNAs
Prostate cancer

Access to Document

10.1016/j.canlet.2012.02.011

Cite this

@article{ce847432b86a4aefb5da9e0c774c6324,

title = "Epigenetic biomarkers in prostate cancer: Current and future uses.",

abstract = "Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.",

keywords = "Biomarkers, DNA methylation, Epigenetics, Histone modifications, MicroRNAs, Prostate cancer",

author = "Karen Chiam and Carmella Ricciardelli and Tina Bianco-Miotto",

year = "2014",

month = jan,

day = "28",

doi = "10.1016/j.canlet.2012.02.011",

language = "English",

volume = "342",

pages = "248--256",

journal = "Cancer Letters",

issn = "0304-3835",

number = "2",

}

TY - JOUR

T1 - Epigenetic biomarkers in prostate cancer: Current and future uses.

AU - Chiam, Karen

AU - Ricciardelli, Carmella

AU - Bianco-Miotto, Tina

PY - 2014/1/28

Y1 - 2014/1/28

N2 - Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.

AB - Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.

KW - Biomarkers

KW - DNA methylation

KW - Epigenetics

KW - Histone modifications

KW - MicroRNAs

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84888200099&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.02.011

DO - 10.1016/j.canlet.2012.02.011

M3 - Review article

VL - 342

SP - 248

EP - 256

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -

Epigenetic biomarkers in prostate cancer: Current and future uses.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this